Enlivex Therapeutics Ltd.(ENLV)

Biotechnology · Ness Ziona, TA

$0.36-0.01 (-1.88%)

Delayed quote: Oct 6, 2026, 10:13 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:16:34.370Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:16:34.370Z.

Quote observation: 2026-10-06T14:13:37.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,978,732
Total debt · period ending 2026-06-30: 17,248,000
Cash · period ending 2026-06-30: 5,518,000
TTM operating EBITDA · period ending 2026-06-30: -20,286,000

FMP input reference: 16b0ce149acf027305ec47ed69e441f7c4eae43bc3095c7aeda967d53938ba16

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ENLV EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ENLV Competitors' EV/EBITDA Ratio

ENLV

Enlivex Therapeutics Ltd.

Current

Market Cap

$5.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDIO

Cardio Diagnostics Holdings, Inc.

vs ENLV

Market Cap

$6.10M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCY

Lucyd, Inc

vs ENLV

Market Cap

$5.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMRA

Biomerica, Inc.

vs ENLV

Market Cap

$6.22M

EV/EBITDA Ratio

N/A

TTM Avg

96.60x

3Y Avg

88.71x

5Y Avg

504.98x

FEMY

Femasys Inc.

vs ENLV

Market Cap

$6.22M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

vs ENLV

Market Cap

$5.80M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACXP

Acurx Pharmaceuticals, Inc.

vs ENLV

Market Cap

$5.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBS

Intelligent Bio Solutions Inc.

vs ENLV

Market Cap

$5.57M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENVB

Enveric Biosciences, Inc.

vs ENLV

Market Cap

$6.58M

EV/EBITDA Ratio

N/A

TTM Avg

34.26x

3Y Avg

34.26x

5Y Avg

668.76x

ENSC

Ensysce Biosciences, Inc.

vs ENLV

Market Cap

$6.63M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Enlivex Therapeutics Ltd. (ENLV)	$5.98M	N/A	N/A	N/A	N/A
Cardio Diagnostics Holdings, Inc. (CDIO)vs ›	$6.10M	N/A	N/A	N/A	N/A
Lucyd, Inc (LUCY)vs ›	$5.92M	N/A	N/A	N/A	N/A
Biomerica, Inc. (BMRA)vs ›	$6.22M	N/A	96.60x	88.71x	504.98x
Femasys Inc. (FEMY)vs ›	$6.22M	N/A	N/A	N/A	N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs ›	$5.80M	N/A	N/A	N/A	N/A
Acurx Pharmaceuticals, Inc. (ACXP)vs ›	$5.55M	N/A	N/A	N/A	N/A
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.57M	N/A	N/A	N/A	N/A
Enveric Biosciences, Inc. (ENVB)vs ›	$6.58M	N/A	34.26x	34.26x	668.76x
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.63M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics